The stock will trade on PROACT 1 enrollment milestones and the Q2 2027 topline readout, not quarterly financials. Monitor for enrollment completion announcements in mid-2026 and any FDA interactions. Cash runway into mid-2027 provides no near-term financing urgency, but the burn rate implies a potential capital raise before the readout if enrollment delays occur.
PROK drugs
PROK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 15 $1.66entry
- T+1 · 6mo ago −3.01%α −2.95% · $1.61
- T+5 · 6mo ago +5.42%α +4.46% · $1.75
- T+20 · 5mo ago +0.60%α −1.52% · $1.67
- T+60 · 3mo ago −3.01%α −7.53% · $1.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ProKidney reported Q1 2026 EPS of -$0.14, essentially in line with the -$0.14 consensus (a 1.8% miss), with negligible revenue of $226K. The key catalyst is the on-track enrollment completion for the Phase 3 PROACT 1 accelerated approval analysis in mid-2026, with pivotal topline eGFR slope results expected in Q2 2027. Cash burn continues, with $224.9M in cash supporting operations into mid-2027, but no fundamental financial improvement was reported.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.14 vs consensus -$0.14 (in line, 1.8% miss)
- Revenue of $226K vs consensus $100K (beat, but immaterial for a clinical-stage biotech)
- Cash, cash equivalents and marketable securities: $224.9M as of March 31, 2026, down from $270.0M at year-end 2025
- Net loss before noncontrolling interest: $42.6M in Q1 2026 vs $38.0M in Q1 2025
- R&D expenses increased to $33.8M from $27.3M YoY, driven by PROACT 1 study costs
- Phase 3 PROACT 1 enrollment on track to complete in mid-2026; pivotal topline results expected Q2 2027
- FDA confirmed eGFR slope as surrogate endpoint for accelerated approval under RMAT designation
- Phase 2 REGEN-007 results published in CJASN in January 2026
- Cash runway into mid-2027
Financial Impact
No material financial impact from Q1 results; cash burn of ~$45M per quarter continues. Key value driver is the PROACT 1 readout in Q2 2027.
Risk Factors
- PROACT 1 enrollment delays or failure to meet eGFR slope endpoint
- Cash burn may require dilutive financing before mid-2027 if enrollment or readout is delayed
- Regulatory risk: FDA may require additional studies beyond PROACT 1 for approval
- Competition from other CKD therapies (SGLT2 inhibitors, finerenone)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296021 |
Track record
13 reports on PROK
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
- Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
- May 15, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers